Decima 50 mg Injection

Benefits

• Improves production of healthy blood cells

• Reduces dependence on blood transfusions

• Slows progression of myelodysplastic syndromes

• Helps restore normal gene function in bone marrow cells

• Proven treatment option for high-risk MDS patients

Indications and Usage

Decima 50 mg Injection is indicated for the treatment of patients with:

• Myelodysplastic Syndromes (MDS)

  • Refractory anemia

  • Refractory anemia with ringed sideroblasts

  • Refractory anemia with excess blasts

  • Refractory anemia with excess blasts in transformation

• Chronic Myelomonocytic Leukemia (CMML)

• Intermediate-2 and high-risk IPSS (International Prognostic Scoring System) groups

• Previously treated and untreated, de novo and secondary MDS

Treatment should be initiated and supervised by an oncologist or hematologist

How it Works

Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation. This action restores normal control of cell growth and differentiation in abnormal bone marrow cells. In rapidly dividing cancer cells, it also causes cell death, while non-dividing cells are less affected

Dosage & Administration

Decima 50 mg Injection is administered intravenously by trained healthcare professionals only.

Two recommended regimens:

Regimen 1

• 15 mg/m² IV infusion over 3 hours

• Every 8 hours for 3 days

• Repeated every 6 weeks

Regimen 2

• 20 mg/m² IV infusion over 1 hour

• Once daily for 5 days

• Repeated every 4 weeks

• Patients should receive at least 4 cycles

• Dose adjustments may be required based on blood count recovery

• Regular monitoring of CBC, platelets, liver and kidney function is mandatory

Side Effects

Common side effects:

• Neutropenia

• Thrombocytopenia

• Anemia

• Fatigue

• Fever

• Nausea

• Diarrhea or constipation

• Cough

• Hyperglycemia

Serious side effects:

• Severe infections

• Febrile neutropenia

• Severe bleeding

• Liver function abnormalities

• Pulmonary edema

• Cardiac rhythm disturbances

• Intracranial hemorrhage

Warning and Precaution

• Causes severe neutropenia and thrombocytopenia

• High risk of infections – early use of antibiotics or growth factors may be required

• Not recommended during pregnancy – may cause fetal harm

• Women should avoid pregnancy during treatment and for 1 month after

• Men should avoid fathering a child during treatment and for 2 months after

• Use caution in patients with liver or kidney impairment

• Not to be used in uncontrolled infections

• Cytotoxic drug – proper handling and disposal required